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Detection of Chromosomal Instability by Fluorescence in Situ 
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Purpose: The aim of this study was to evaluate prognostic impor-
tance of chromosomal instability (CIN) in non-small cell lung cancers 
(NSCLC). We examined the relationship between CIN detected by 
ﬂuorescence in situ hybridization and survival in patients with NSCLC 
and subgroup. 
Experimental Design: 132 surgical specimens of NSLC were studied. 
The patients included 109 men and 23 women, with an median age of 
59 years. Tumors included 64 adenocarcinomas (AC), 68 squamous 
cell carcinomas (SCC). The pathologic stage was IA in 22, IB in 53, 
IIA in 5, IIB in 28, IIIA in 18, and IIIB in 6 cases. Multi-target DNA 
FISH assay (LAVysion, Vysis) was used to determine which tumors 
carried CIN. Survival were compared according to the following fac-
tors: gender, age, histology, T factor, N factor, CIN and smoking status. 
Results: Fifty tumors (37.9%) showing numerical heterogeneity in 
all four examined chromosomes were judged to be carrying CIN. The 
percentage of CIN was signiﬁcantly higher in Adenocarcinoma group 
than squamous cell carcinoma group. (54.7% vs 22.1%, p < 0.001) 
The rate of lymph node involvement was lower in CIN positive group. 
(26% vs 43.9%, p = 0.039) The CIN positive group had lower smoking 
history. (26.0 ± 24.0 vs 35.1 ± 24.2, p = 0.036) In multivariate analysis, 
there was no signiﬁcant differences two groups. Kaplan-Meier survival 
curves according to CIN status shows no signiﬁcant differences. Log-
rank test revealed only gender factor predicted a poor survival.
Conclusions: Our study demonstrates that CIN is more frequent in AC 
than SCC. But CIN is not an independent prognostic factor in the group 
of patients with NSCLC and in the subgroups: both with AC and SCC. 
P2-068 BSTB: Prognostic Factors Posters, Tue, Sept 4 
CD63 as a biomarker for predicting the clinical outcomes in non-
small cell lung cancers
Kwon, Mi Seon1 Park, Jae-Kil2 Shin, Seung-Hun3 Lee, Kyo Young4 
Chung, Yeun-Jun3 
1 Department of Pathology, Dankook University College of Medicine, 
Chonahn, Korea 2 Department of Thoracic & Cardiovascular Surgery, 
St Mary’s Hospital, The Catholic University of Korea, Seoul, Korea 3 
Department of Microbiology, The Catholic University of Korea, Seoul, 
Korea 4 Department of Pathology, The Catholic University of Korea, 
Seoul, Korea 
Background: The prognosis of lung cancer is still poor, since there are 
few early detection tools available yet. So, it is important to identify 
more efﬁcient and clinically applicable biomarkers associated with the 
prognosis in as earlier stages as possible.
Method: In this study, we ﬁrstly observed the expression proﬁle of 
CD63 in 33 cases of non-small cell lung cancers (NSCLC) using real-
time quantitative RT-PCR. To explore the potential of this molecule as 
a prognostic biomarker for lung cancer subtypes, we constructed tissue 
microarrays with 90 NSCLCs. Then immunohistochemistry analysis 
was performed with anti-CD63 antibody. Signiﬁcance of the associa-
tion between CD63 expression status and clinicopathological param-
eters was tested by Chi-square test and two-sided Fisher’s exact test 
using SPSS version 12.0 and STATA version 7.0 software.
Result: Majority of NSCLCs (75.8%) showed lower CD63 RNA level 
(less than half) than normal tissue. Notably, all SqCs showed low-ex-
pression except one case, while AdCs showed diverse range of expres-
sion. CD63 protein expression level was largely compatible with RNA 
level. Totally, 63.3% of NSCLC were CD63 protein expression nega-
tive. All SqCs were negative, while majority (70.2%) of adenocarcino-
mas (AdCs) were positive. CD63 protein negativity was signiﬁcantly 
associated with SqCs type, larger tumor size, and advanced stage. In 
AdCs, CD63 negativity was associated with poor survival (p=0.008). 
This association was also signiﬁcant in earlier stage (I and II) AdCs 
(p=0.041), but not in advanced stage AdCs. After being adjusted for 
age and sex by Cox regression and stratiﬁed by stages, CD63 negativity 
still showed borderline association with poor survival as an indepen-
dent predictor (p=0.076, HR=2.3).
Conclusion: Taken together, these results suggest that CD63 can be a 
biomarker for predicting the prognosis in earlier stage of lung AdCs. 
Our ﬁndings can be a clue to investigate the role of CD63 in tumori-
genesis of AdCs of lung and other cancers.
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Growth Factor Receptor (EGFR) profile in patients with resectable 
non small cell lung cancer
Coate, Linda; Barr, Martin; O’Callaghan, Dermot; Barrett, Ciara; 
O’Byrne, Kenneth; Gately, Kathy 
St. James’ Hospital, Dublin, Ireland
Background: Lung cancer is the biggest cause of cancer death in the 
US and Europe. Recently an increased understanding of the molecu-
lar biology of Non-small cell lung cancer (NSCLC) has led to the 
introduction of novel targeted therapies. The epidermal growth factor 
(EGFR), commonly overexpressed in NSCLC has emerged as an at-
tractive target. This has led to the development of the EGFR tyrosine 
kinase inhibitors (TKIs) erlotinib and geﬁtinib and the monoclonal 
antibody directed against the EGFR, cetuximab. Other agents targeting 
the EGFR are in various stages of development. Several studies have 
shown that patients with somatic mutations in the EGFR TK domain 
are more sensitive to TKIs while mutations in K-ras, a mediator of 
EGFR signalling, are associated with resistance. Overexpression of the 
EGFR, detected by immunohistochemistry does not predict response 
to anti-EGFR therapy. Determining gene copy of the EGFR using 
ﬂuorescent in situ hybridisation (FISH) appears to predict response to 
the TKI’s. Determining gene copy number of the EGFR using RT-PCR 
technology is not well explored and the prognostic value of this is as 
yet unknown. 
Aim: The natural history of these mutations is unknown therefore the 
aim of this study is to examine a cohort of 200 patients who underwent 
resection for NSCLC, between 2002-2004 in St. James’Hospital, for 
EGFR/K-ras mutational status and EGFR ampliﬁcation and expression. 
Methods: DNA is extracted from the parafﬁn-embedded tumour tis-
sue of each patient. Exons 19 and 21 of the EGFR gene and exon 2 of 
the K-ras gene are ampliﬁed using nested PCR. The PCR product is 
bidirectionally sequenced using BigDye Terminator v3.1 on the ABI 
3100 sequencing instrument. The DNA is also subjected to quantita-
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tive Real-time PCR to analyse EGFR gene copy number using the ABI 
7000 sequence detection system. The same specimens are analysed to 
identify expression of EGFR using standard immunohistochemistry 
techniques. 
Results: 100 samples have been analysed to date. EGFR mutations 
occurred in ~6% of these. K-ras mutations occurred in ~8%. EGFR 
overexpression occurred in ~40%. Data including gene copy number 
from the complete cohort of patients will be linked to survival and 
other clinical parameters. 
Conclusion: The level of mutations in the EGFR are low. This may be 
explained by the fact that our study population was entirely Caucasian, 
predominantly smokers or ex smokers and the tumour sample popula-
tion was not enriched for adenocarcinoma. The K-ras mutation rate is 
consistent with a predominantly smoking population. The detection 
of these mutations in the future may become important determinant in 
the selection of therapy as there is some evidence to suggest that K-ras 
mutated tumours are not only resistant to the TKI’s but also their growth 
may be accelerated with TKI treatment. The relevance of determining 
EGFR gene copy number using RT-PCR technology is as yet unclear but 
a planned survival analysis may determine its prognostic signiﬁcance.
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Elevated expression of Carcinoembryonic Antigen-related Cell 
Adhesion Molecule 1 (CEACAM-1) is associated with increased 
angiogenic potential in non-small cell lung cancer
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Purpose: Recent studies have challenged the previously postulated 
concept of a tumor-suppressive effect of Carcinoembryonic Antigen-
related Cell Adhesion Molecule 1 (CEACAM-1). A possible angiogenic 
inﬂuence of CEACAM-1 in non small-cell lung cancer (NSCLC) 
has not been investigated so far. Therefore, we examined microves-
sel density (MVD) and CEACAM-1 expression in primary NSCLC 
and analyzed their possible correlations under consideration of their 
prognostic effects.
Patients and methods: Specimens from 82 consecutive patients with 
completely resected NSCLC were stained immunohistochemically 
using the monoclonal anti-CEACAM-1 antibody 4D1/C2 and the 
monoclonal anti-CD31 antibody JC70A. The prognostic relevance of 
CEACAM-1 expression and MVD was evaluated by univariate Kaplan-
Meier and multivariate Cox regression analysis. The median follow-up 
period was 75 months (range 10 to 156 months).
Results: A high MVD (i.e.≥31 microvessels/x400 microscopic ﬁeld) 
was observed more frequently in tumors with high CEACAM-1 
expression (i.e.≥66% stained tumor cells) than in tumors with low 
CEACAM-1 expression (61.8 versus 33.3%, respectively; p=0.01). In 
univariate survival analyses, high CEACAM-1 expression and high 
MVD were associated with development of distant metastasis (p=0.011 
and 0.022 respectively) and decreased cancer-related survival (p=0.046 
and p=0.006 respectively). Multivariate Cox regression analysis 
demonstrated that the prognostic impact of CEACAM-1 depended on 
the prognostic inﬂuence of MVD, while MVD itself represented an 
independent prognosticator for unfavorable cancer-related survival 
(p=0.021; relative risk, 2.1; 95% conﬁdence interval, 1.1-4.0).
Conclusion: Here we show for the ﬁrst time that high CEACAM-1 ex-
pression is associated with an increased angiogenic activity in NSCLC, 
and that the prognostic inﬂuence of CEACAM-1 might be derived from 
this association. 
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PLOD2 and TTF1 expression as prognostic variables in selection 
for adjuvant treatment in early stage lung adenocarcinoma
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Background: To examine recent gene and protein expression proﬁling 
reports and a meta analysis of Thyroid Transcription Factor 1 protein 
expression for reproducibility as prognostic factors for survival, using 
two online Lung Cancer Micro array data sources as having prognostic 
potential in early Adenocarcinaoma of the Lung. To assess whether 
a poor prognostic grouping can be divided into treatment prognostic 
subgroups by genes selected for 5 Fluorouracil sensitivity or resistance. 
Methods: Two online micro array data sets were used to assess 
reproducibility of reported proﬁles of prognostic signatures. The gene 
probe for TTF1 was examined for survival association in the two data 
sets. Genes found to be signiﬁcant for survival in the ﬁrst data set were 
tested in a separate test group. Gene probes found to be signiﬁcant in 
both groupings were assessed, as a categorized variables, for predicting 
survival.
Results: The high expression of a probe for the gene procollagen-ly-
sine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) and the low expression 
of a probe for TTF1 gene were signiﬁcant and increased the hazard for 
a poor survival. The signiﬁcance was seen in both micro array data sets.
The hazard for PLOD2, 95% CI 1.14 to 2.13 and for TTF1 0.51 to 0.98. 
PLOD2 was a better discriminator for survival to 18, 24 or 30 months. 
PLOD2 gene expression but not TTF1 remained an important variable 
if age, sex, grade, size or bronchoalveolar features were examined as 
covariables.
That genes possibly important in 5FU sensitivity can be used to cluster 
patients with a poor prognostic high PLOD2 expression or low TTF1 
expression.
Conclusion: That TTF1 has achieved further proof as a prognostic 
factor in early Adenocarcinomas of the lung. That PLOD2 a gene as-
sociated with a ﬁbroblastic response to serum might be important in 
early cancer progression in Adenocarcinoma of the lung and deserves 
further investigation. That patient categorization using prognostic genes 
for 5FU sensitivity is possible and should be considered in a prospec-
tive trial.
